Active Trials

These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.

Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.

Trial name A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)

Type of trial Phase III

Trial ID NCT04348656

Health Canada Status Health Canada approved

Trial Status Open

Location

Ontario, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon

Trial description

CONCOR-1 Trial Description: A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness. This is a prospective randomized control trial that is comparing convalescent plasma to standard of care in adult patients admitted to Canadian hospitals with respiratory complications from COVID-19. Intervention will be 500 mL of convalescent plasma from donors with SAR-CoV-2 neutralizing antibodies in addition to standard of care. We are not yet enrolling patients. There will be between 40-60 sites participating across Canada.

Study team

Donald Arnold

MD

Hamilton Health Sciences Centre

Trial name Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

Type of trial Phase II

Trial ID NCT 04315298

Health Canada Status Does not require Health Canada approval

Trial Status Open

Location

United States, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon

Trial description

The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of severity strata. (This initiative also has pan-Canadian sites.)

Study team

Trial name Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)

Type of trial Phase II

Trial ID NCT 04330690

Health Canada Status Does not require Health Canada approval

Trial Status Open

Location

Alberta, British Columbia, Ontario, Quebec, Manitoba, Saskatchewan, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Yukon, Northwest Territories, Nunavut

Trial description

This study is an adaptive, randomized, open-label, controlled clinical trial.Subjects will be randomized to receive either standard-of-care products or the study medication plus standard of care, while being hospitalized for COVID-19. Lopinavir/ritonavir will be administered 400 mg/100 mg orally (or weight based dose adjustment for children) for a 14-day course, or until discharge from hospital, whichever occurs first

Study team